June 1, 2024Journal of Clinical Oncology

A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors.

View Full Paper

Ask AI

Bookmark

Trial protocol evaluates IK-595 monotherapy in advanced solid tumors harboring RAS alterations, aiming to overcome resistance from CRAF reactivation.
Phase 1 trial protocol uses a Bayesian optimal interval design to assess safety and establish recommended dosing across 30-day treatment cycles.
Findings may establish a broader therapeutic window for MEK phosphorylation inhibition, with initial cohort cleared and dose escalation enrolling.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial reports preliminary safety and tolerability of IK-595 in advanced solid tumors, highlighting a novel approach to bypass pathway reactivation.

Cite This Study

Lakhani et al. (2024) studied this question.

synapsesocial.com/papers/68e674e7b6db6435875ff7e2 https://doi.org/10.1200/jco.2024.42.16_suppl.tps3185

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reports preliminary safety and tolerability of IK-595 in advanced solid tumors, highlighting a novel approach to bypass pathway reactivation.

A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors.

Key Points

Discussion

Implication

Cite This Study

A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider